We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Receives €3.7 Million Grant for Cystic Fibrosis Program

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Receives €3.7 Million Grant for Cystic Fibrosis Program"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Galapagos NV announces that it has been awarded a €3.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT).

The three-year project "Disease-modifying drug discovery in cystic fibrosis" focuses on Galapagos' cystic fibrosis (CF) program based on novel drug targets, with the goal to deliver a pre-clinical candidate. Galapagos will collaborate on this project with the Center for Human Genetics at the KU Leuven.

"Galapagos is breaking new ground in CF with its novel targets. We are pleased that the IWT chooses to support these efforts. The collaboration with the Center for Human Genetics helps us to prioritize the novel targets which could make the most difference to CF patients," said Graham Dixon, SVP Drug Discovery for Galapagos. "This grant increases the chances of delivering a pre-clinical candidate by our target date of 2013."